You are in the accessibility menu

Please use this identifier to cite or link to this item: http://acervodigital.unesp.br/handle/11449/69491
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBarbosa, Guilherme Correa-
dc.contributor.authorMoreno, Vânia-
dc.contributor.authorJuliani, Carmen Maria Casquel Monti-
dc.contributor.authorSpiri, Wilza Carla-
dc.contributor.authorMolina Lima, Silvana Andrea-
dc.date.accessioned2014-05-27T11:22:23Z-
dc.date.accessioned2016-10-25T18:23:30Z-
dc.date.available2014-05-27T11:22:23Z-
dc.date.available2016-10-25T18:23:30Z-
dc.date.issued2007-01-01-
dc.identifierhttp://dx.doi.org/10.4025/actascihealthsci.v29i1.118-
dc.identifier.citationActa Scientiarum - Health Sciences, v. 29, n. 1, p. 19-23, 2007.-
dc.identifier.issn1679-9291-
dc.identifier.urihttp://hdl.handle.net/11449/69491-
dc.identifier.urihttp://acervodigital.unesp.br/handle/11449/69491-
dc.description.abstractThe present work aims to raise the costs of high-cost drugs used to treat patients of Refractory Schizophrenia in ambulatory unit. The study was carried out in the Psychosocial Support Center, which treated 33 patients with these medications, during the period of June, 2005 to May, 2006. Data analysis disclosed that the mostly used drugs to treat the carriers of Refractory Schizophrenia were: clozapina and risperidona. It was observed that the treatment with olanzapina is more expensive than that with risperidona. The study concluded that the analysis of the consumption and costs of drugs of high cost is necessary to subside better management of the expenses and new investments in the service. Moreover, the necessity of more studies in the area was also identified to contribute with the control of costs.en
dc.format.extent19-23-
dc.language.isopor-
dc.sourceScopus-
dc.subjectAtypical antipsychotics-
dc.subjectCosts-
dc.subjectSchizophrenia-
dc.subjectclozapine-
dc.subjectneuroleptic agent-
dc.subjectolanzapine-
dc.subjectquetiapine-
dc.subjectrisperidone-
dc.subjectziprasidone-
dc.subjectambulatory care-
dc.subjectclinical article-
dc.subjectcontrolled study-
dc.subjectcost control-
dc.subjectcost effectiveness analysis-
dc.subjectdrug cost-
dc.subjectdrug use-
dc.subjecthuman-
dc.subjectmental health service-
dc.subjectschizophrenia-
dc.titleMedicação de alto custo para portador de sofrimento psíquico: Um estudo preliminar dos custospt
dc.title.alternativeHigh cost drugs for carrier of psychic suffering: A preliminary study of costsen
dc.typeoutro-
dc.contributor.institutionFaculdade de Medicina de Marília (FAMEMA)-
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)-
dc.description.affiliationÁrea de Enfermagem Psiquiátrica Faculdade de Medicina de Marilia, Marilia, São Paulo-
dc.description.affiliationDepartamento de Enfermagem Faculdade de Medicina de Botucatu Universidade Estadual Paulista, Rubião Junior, s/n, 18618-970 Botucatu, São Paulo-
dc.description.affiliationUnespDepartamento de Enfermagem Faculdade de Medicina de Botucatu Universidade Estadual Paulista, Rubião Junior, s/n, 18618-970 Botucatu, São Paulo-
dc.identifier.doi10.4025/actascihealthsci.v29i1.118-
dc.rights.accessRightsAcesso aberto-
dc.identifier.file2-s2.0-55049109893.pdf-
dc.relation.ispartofActa Scientiarum: Health Sciences-
dc.identifier.scopus2-s2.0-55049109893-
Appears in Collections:Artigos, TCCs, Teses e Dissertações da Unesp

There are no files associated with this item.
 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.